# Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults

> **NCT07513168** · PHASE4 · RECRUITING · sponsor: **Asian Institute Of Medical Sciences** · enrollment: 60 (estimated)

## Conditions studied

- Obesity
- Weight Reduction
- Cardiometabolic Risk Factors

## Interventions

- **DRUG:** Locally available low-dose semaglutide (0.25 mg, 0.5 mg, 1 mg)

## Key facts

- **NCT ID:** NCT07513168
- **Lead sponsor:** Asian Institute Of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-01
- **Primary completion:** 2026-08-30
- **Final completion:** 2026-12-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07513168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07513168, "Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07513168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*